title: Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
abstract: Neuromedin B (NMB), a member of the bombesin family of peptides, is an autocrine growth factor for many lung cancer cells. The present study investigated the ability of NMB to cause transactivation of the epidermal growth factor (EGF) receptor in lung cancer cells. By Western blot, addition of NMB or related peptides to NCI-H1299 human non-small cell lung cancer (NSCLC) cells, caused phosphorylation of Tyr(1068) of the EGF receptor. The signal was amplified using NCI-H1299 cells stably transected with NMB receptors. The transactivation of the EGF receptor or the tyrosine phosphorylation of ERK caused by NMB-like peptides was inhibited by AG1478 or gefitinib (tyrosine kinase inhibitors) and NMB receptor antagonist PD168368 but not the GRP receptor antagonist, BW2258U89. The transactivation of the EGF receptor caused by NMB-like peptides was inhibited by GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor), or transforming growth factor (TGF)alpha antibody. The transactivation of the EGF receptor and the increase in reactive oxygen species caused by NMB-like peptides was inhibited by N-acetylcysteine (NAC) or Tiron. Gefitinib inhibited the proliferation of NCI-H1299 cells and its sensitivity was increased by the addition of PD168368. The results indicate that the NMB receptor regulates EGF receptor transactivation by a mechanism dependent on Src as well as metalloprotease activation and generation of reactive oxygen species.
authors.affiliation: Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, Bethesda, Maryland 20892, USA. moodyt@mail.nih.gov
authors.forename: Terry W
authors.initials: TW
authors.lastname: Moody
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Berna
authors.forename: Samuel
authors.initials: S
authors.lastname: Mantey
authors.forename: Veronica
authors.initials: V
authors.lastname: Sancho
authors.forename: Lisa
authors.initials: L
authors.lastname: Ridnour
authors.forename: David A
authors.initials: DA
authors.lastname: Wink
authors.forename: Daniel
authors.initials: D
authors.lastname: Chan
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giaccone
authors.forename: Robert T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D000077156:Gefitinib; D006801:Humans; D015287:Neurokinin B / Q000031:analogs & derivatives / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D019000:Phosphotyrosine / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D018004:Receptors, Bombesin / Q000235:genetics / Q000378:metabolism*; D015533:Transcriptional Activation / Q000187:drug effects / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D004791:Enzyme Inhibitors; D011799:Quinazolines; D017382:Reactive Oxygen Species; D018004:Receptors, Bombesin; D019000:Phosphotyrosine; D015287:Neurokinin B; C038393:neuromedin B; D066246:ErbB Receptors; D000077156:Gefitinib; D000111:Acetylcysteine
references.citation: Cancer Res. 2006 Jan 15;66(2):944-50
references.pmid: 16424029
references.citation: Eur J Pharmacol. 2000 Dec 8;409(2):133-42
references.pmid: 11104826
references.citation: Exp Cell Res. 2003 Nov 1;290(2):437-46
references.pmid: 14568001
references.citation: Pulm Pharmacol Ther. 1999;12(5):291-302
references.pmid: 10545285
references.citation: J Natl Cancer Inst. 2002 Mar 6;94(5):375-83
references.pmid: 11880476
references.citation: J Biol Chem. 2004 May 28;279(22):23580-9
references.pmid: 15016826
references.citation: Cancer Res. 1992 May 1;52(9 Suppl):2732s-2736s
references.pmid: 1563005
references.citation: Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):489-95
references.pmid: 11304462
references.citation: Clin Cancer Res. 2003 Jun;9(6):2316-26
references.pmid: 12796401
references.citation: Oncogene. 2003 Sep 18;22(40):6183-93
references.pmid: 13679857
references.citation: Oncogene. 2004 Jan 29;23(4):991-9
references.pmid: 14647423
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1414-24
references.pmid: 17431120
references.citation: J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11
references.pmid: 10454496
references.citation: J Cell Biochem Suppl. 1996;24:237-46
references.pmid: 8806106
references.citation: Cancer Res. 2004 Sep 1;64(17):6166-73
references.pmid: 15342401
references.citation: Nature. 1985 Aug 29-Sep 4;316(6031):823-6
references.pmid: 2993906
references.citation: Cell Growth Differ. 1995 Nov;6(11):1427-35
references.pmid: 8562481
references.citation: J Pharmacol Exp Ther. 1992 Oct;263(1):311-7
references.pmid: 1328611
references.citation: Clin Cancer Res. 2002 Apr;8(4):1139-46
references.pmid: 11948125
references.citation: Mol Cancer Ther. 2004 Apr;3(4):465-72
references.pmid: 15078990
references.citation: Cell Signal. 2003 Oct;15(10):945-53
references.pmid: 12873708
references.citation: Pflugers Arch. 2006 Apr;452(1):16-24
references.pmid: 16261333
references.citation: Biochim Biophys Acta. 2006 Aug;1766(1):23-41
references.pmid: 16490321
references.citation: Mol Pharmacol. 1992 Dec;42(6):1058-68
references.pmid: 1336112
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: Neoplasia. 2005 Apr;7(4):426-31
references.pmid: 15967120
references.citation: J Biol Chem. 1997 Oct 10;272(41):26062-71
references.pmid: 9325344
references.citation: Pharmacol Rev. 2008 Mar;60(1):1-42
references.pmid: 18055507
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Biol Chem. 1991 Oct 5;266(28):18771-9
references.pmid: 1655761
references.citation: Cancer Res. 2006 Oct 1;66(19):9601-8
references.pmid: 17018617
references.citation: Peptides. 2001 Apr;22(4):689-99
references.pmid: 11311741
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Biol Chem. 1997 Jan 3;272(1):217-21
references.pmid: 8995250
references.citation: Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94
references.pmid: 9873586
references.citation: Peptides. 1996;17(8):1337-43
references.pmid: 8971929
references.citation: Exp Cell Res. 2007 Apr 15;313(7):1361-72
references.pmid: 17349623
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7117-25
references.pmid: 17145836
references.citation: Can J Physiol Pharmacol. 2003 Feb;81(2):159-67
references.pmid: 12710530